International Journal of Urology最新文献

筛选
英文 中文
Magnetic Resonance Imaging Findings and Prostate-Specific Antigen Density-Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate 磁共振成像结果和前列腺特异性抗原密度为基础的风险分层推迟术前活检的候选钬激光前列腺摘除。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-05 DOI: 10.1111/iju.70694
Taku Mitome, Hibiki Hirose, Nanaho Demizu, Mei Tokumoto, Shinichi Takebe, Tomoharu Morikawa, Ryota Morinaga, Shuko Yoneyama, Akitoshi Takizawa
{"title":"Magnetic Resonance Imaging Findings and Prostate-Specific Antigen Density-Based Risk Stratification for Deferring a Separate Preoperative Biopsy in Candidates for Holmium Laser Enucleation of the Prostate","authors":"Taku Mitome,&nbsp;Hibiki Hirose,&nbsp;Nanaho Demizu,&nbsp;Mei Tokumoto,&nbsp;Shinichi Takebe,&nbsp;Tomoharu Morikawa,&nbsp;Ryota Morinaga,&nbsp;Shuko Yoneyama,&nbsp;Akitoshi Takizawa","doi":"10.1111/iju.70694","DOIUrl":"10.1111/iju.70694","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To evaluate whether a separate preoperative prostate biopsy can be deferred using magnetic resonance imaging (MRI) and prostate-specific antigen density (PSAD) in candidates for holmium laser enucleation of the prostate (HoLEP).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed 625 patients who underwent HoLEP. In the high prostate-specific antigen (PSA) cohort (≥ 4.0 ng/mL, <i>n</i> = 455), the diagnostic performance of PSAD was evaluated. In patients without a prior biopsy within 1 year who underwent preoperative MRI (<i>n</i> = 126), candidates for biopsy deferral (MRI-negative and PSAD &lt; 0.20 ng/mL/mL, <i>n</i> = 95) were assessed. Clinically significant prostate cancer (csPCa) detection rates and histologically validated negative predictive values (NPVs) were determined using simultaneous peripheral zone (PZ) biopsy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Multivariable analysis identified PSAD ≥ 0.20 ng/mL/mL as an independent predictor of csPCa (odds ratio: 3.80, 95% confidence interval [CI]: 1.35–10.64, <i>p</i> = 0.011). In patients without a prior biopsy within 1 year (<i>n</i> = 343), PSAD &lt; 0.20 ng/mL/mL achieved a specificity of 85.9% and a biopsy deferral rate of 84.8%. Among 126 MRI-evaluated patients, the combined criteria (MRI-negative and PSAD &lt; 0.20 ng/mL/mL) yielded a sensitivity of 83.3%, specificity of 78.3%, an NPV of 98.9% (94/95), and a biopsy deferral rate of 75.4% (95/126). The histologically validated NPV obtained via simultaneous PZ biopsy (<i>n</i> = 77) was 98.7% (76/77).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Combining negative MRI and PSAD &lt; 0.20 ng/mL/mL demonstrated a high NPV for csPCa and may allow the deferral of separate preoperative biopsies in selected patients with large-volume benign prostatic hyperplasia (BPH).</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149342133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Surgical Technique: Prostate Cancer Assessment and Treatment Sequencing Before HoLEP 超越外科技术:HoLEP前前列腺癌评估和治疗顺序。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-03 DOI: 10.1111/iju.70698
Nicola Giudici, Nicolas Arnold, Raphael Röthlisberger
{"title":"Beyond Surgical Technique: Prostate Cancer Assessment and Treatment Sequencing Before HoLEP","authors":"Nicola Giudici,&nbsp;Nicolas Arnold,&nbsp;Raphael Röthlisberger","doi":"10.1111/iju.70698","DOIUrl":"10.1111/iju.70698","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis 新佐剂Enfortumab Vedotin联合Pembrolizumab治疗肌肉浸润性膀胱癌的药理学协同作用定量评价:一项基于copula的二次分析。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-03 DOI: 10.1111/iju.70699
Makito Miyake
{"title":"Editorial Comment to Quantitative Evaluation of Pharmacologic Synergy for Neoadjuvant Enfortumab Vedotin Plus Pembrolizumab in Muscle-Invasive Bladder Cancer: A Copula-Based Secondary Analysis","authors":"Makito Miyake","doi":"10.1111/iju.70699","DOIUrl":"10.1111/iju.70699","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Beyond Association: Clarifying the Biological and Clinical Value of Urinary EphA2 in Bladder Cancer 超越关联:阐明尿EphA2在膀胱癌中的生物学和临床价值。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-03 DOI: 10.1111/iju.70697
Muhammad Hanzla Shahzad
{"title":"Beyond Association: Clarifying the Biological and Clinical Value of Urinary EphA2 in Bladder Cancer","authors":"Muhammad Hanzla Shahzad","doi":"10.1111/iju.70697","DOIUrl":"10.1111/iju.70697","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sensitivity of mHSPC Overall Survival Network Estimates to the Historical Docetaxel Bridge mHSPC总体生存网络估计对历史多西他赛桥的敏感性。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-03 DOI: 10.1111/iju.70696
Shugo Yajima, Soichiro Yoshida, Hitoshi Masuda, Yasuhisa Fujii
{"title":"Sensitivity of mHSPC Overall Survival Network Estimates to the Historical Docetaxel Bridge","authors":"Shugo Yajima,&nbsp;Soichiro Yoshida,&nbsp;Hitoshi Masuda,&nbsp;Yasuhisa Fujii","doi":"10.1111/iju.70696","DOIUrl":"10.1111/iju.70696","url":null,"abstract":"","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Five-Year Clinical Outcomes Following Nephrectomy for Renal Cell Carcinoma: Evidence From a Nationwide Japanese Surgical Registry 肾细胞癌切除后的5年临床结果:来自日本全国外科登记的证据。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-02 DOI: 10.1111/iju.70695
Ryuichi Mizuno, Kyoko Yamamoto, Hiroyuki Yamamoto, Shingo Hatakeyama, Shinichi Sakamoto, Takahiro Yasui, Takashi Kobayashi, Toshiyuki Kamoto, Eiji Kikuchi, Akihiro Ito, Haruki Kume
{"title":"Five-Year Clinical Outcomes Following Nephrectomy for Renal Cell Carcinoma: Evidence From a Nationwide Japanese Surgical Registry","authors":"Ryuichi Mizuno,&nbsp;Kyoko Yamamoto,&nbsp;Hiroyuki Yamamoto,&nbsp;Shingo Hatakeyama,&nbsp;Shinichi Sakamoto,&nbsp;Takahiro Yasui,&nbsp;Takashi Kobayashi,&nbsp;Toshiyuki Kamoto,&nbsp;Eiji Kikuchi,&nbsp;Akihiro Ito,&nbsp;Haruki Kume","doi":"10.1111/iju.70695","DOIUrl":"10.1111/iju.70695","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterize mid-term oncological outcomes after nephrectomy for renal cell carcinoma (RCC) in Japan using the National Clinical Database (NCD).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We retrospectively analyzed patients with RCC who underwent nephrectomy between April and December 2018 and had at least 5 years of follow-up recorded in the NCD. Age, sex, nephrectomy type, operative approach, and pathological T category were evaluated. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared with the log-rank test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 16 786 patients registered at 759 institutions, 9065 with available 5-year follow-up were analyzed. Patients aged ≥ 75 years comprised 24.7% of the cohort. Radical and partial nephrectomy were performed in 55.0% and 45.0% of patients, respectively. Median DFS and OS were not reached. Older age and male sex were associated with shorter DFS and OS. Radical nephrectomy and open surgery were also associated with shorter survival. Both DFS and OS decreased significantly with advancing pathological stage, with earlier recurrence in pT3–4 disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This nationwide NCD-based study provides descriptive mid-term survival data for patients with RCC undergoing nephrectomy in Japan. Age, sex, nephrectomy type, operative approach, and pathological stage were associated with survival differences. These findings provide real-world outcome data for patients with available long-term follow-up and a basis for future risk-adjusted analyses.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
External Validation of Existing Nomograms on Indian Prostate Biopsy Data 印度前列腺活检数据中现有nomogram外部验证。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-02 DOI: 10.1111/iju.70690
Mehul Gupta, Kevin Arulraj, Rajeev Kumar
{"title":"External Validation of Existing Nomograms on Indian Prostate Biopsy Data","authors":"Mehul Gupta,&nbsp;Kevin Arulraj,&nbsp;Rajeev Kumar","doi":"10.1111/iju.70690","DOIUrl":"10.1111/iju.70690","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Risk calculators (RC) are predictive models that individualize the risk of prostate cancer (PCa). The current study aimed to validate existing RC for predicting detection of any PCa and clinically significant prostate cancer (csPCa) on prostate biopsy in the Indian population.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Men who underwent transrectal ultrasound-guided prostate biopsy (January 2016–July 2023) at our tertiary care centre were studied. Six tools were evaluated (SWOP-RC, Barcelona-RC, PLUM-RC, PCRC-MRI, Japanese Nomogram, Korean Nomogram) for probability of detection of any PCa and csPCa.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study included 602 patients. PCa was detected in 326 patients (54.2%), including csPCa in 248 (41.2%). For predicting any PCa, both PLUM-RC and SWOP-RC showed an AUC of 0.92 for patients with PSA 10–20 ng/mL and PIRADS-3 on MRI. For predicting csPCa, no single RC demonstrated highest AUCs across all PSA strata. On decision curve analysis, the largest net benefit was seen for individuals with PSA 10–20 ng/mL and PIRADS-3 lesions. Within this criterion, SWOP-RC, PCRC-MRI and Japanese nomogram detected &gt; 10 additional cancers per 100 men while avoiding 40%–55% of biopsies at threshold probabilities ≥ 20%. For most other subgroups, a biopsy-all strategy yielded net benefits similar to the RC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Current Rc demonstrate good applicability (in terms of calibration analysis and discriminatory ability) for prostate cancer prediction in Indian men. The observed net benefit is greatest for individuals with PSA 10–20 ng/mL and PIRADS-3 lesions, and is shown by SWOP-RC for PCa and PCRC-MRI and the Japanese nomogram for csPCa.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prolonged and Nocturnal Hypoglycemia Following Resection of Pheochromocytoma and Paraganglioma: A Prospective Study Using Intermittent-Scanning Continuous Glucose Monitoring 嗜铬细胞瘤和副神经节瘤切除术后长期和夜间低血糖:一项使用间歇扫描连续血糖监测的前瞻性研究。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-02 DOI: 10.1111/iju.70683
Yuki Nakamura, Sho Uehara, Shunya Matsumoto, Masaki Kobayashi, Yudai Ishikawa, Shohei Fukuda, Hiroshi Fukushima, Yuma Waseda, Yosuke Yasuda, Hajime Tanaka, Soichiro Yoshida, Masanori Murakami, Tetsuya Yamada, Yasuhisa Fujii
{"title":"Prolonged and Nocturnal Hypoglycemia Following Resection of Pheochromocytoma and Paraganglioma: A Prospective Study Using Intermittent-Scanning Continuous Glucose Monitoring","authors":"Yuki Nakamura,&nbsp;Sho Uehara,&nbsp;Shunya Matsumoto,&nbsp;Masaki Kobayashi,&nbsp;Yudai Ishikawa,&nbsp;Shohei Fukuda,&nbsp;Hiroshi Fukushima,&nbsp;Yuma Waseda,&nbsp;Yosuke Yasuda,&nbsp;Hajime Tanaka,&nbsp;Soichiro Yoshida,&nbsp;Masanori Murakami,&nbsp;Tetsuya Yamada,&nbsp;Yasuhisa Fujii","doi":"10.1111/iju.70683","DOIUrl":"10.1111/iju.70683","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>To characterize the temporal dynamics and persistence of hypoglycemia following the resection of pheochromocytoma and paraganglioma using intermittent-scanning continuous glucose monitoring.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Twenty-two patients who underwent resection of pheochromocytoma (<i>n</i> = 20) or paraganglioma (<i>n</i> = 2) were prospectively enrolled. Perioperative glucose levels were tracked using intermittent-scanning continuous glucose monitoring (FreeStyle Libre Pro, Abbott), alongside conventional arterial or capillary blood glucose measurement. The endpoints were the time below range, defined as the percentage of time with glucose levels &lt; 70 mg/dL. Postoperative hypoglycemia was defined as blood glucose levels below 70 mg/dL or symptomatic events requiring glucose administration.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eleven patients (50%) experienced postoperative hypoglycemia, with a median onset of 180 min after resection. During a median observation period of 7 days, the mean time below range remained high, ranging from 22% to 37%. Notably, the nocturnal time below range (00:00–06:00) was elevated, reaching 36% to 55%. An increased 7-day time below range was significantly associated with postoperative hypoglycemia and female sex. The time below range from postoperative Day 5 onwards in patients who experienced early postoperative hypoglycemia remained significantly higher than in those without postoperative hypoglycemia. Perioperative hormonal analysis suggested that the rapid resolution of insulin resistance preceded the recovery of insulin secretion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>This prospective study suggests that prolonged susceptibility to nocturnal glucose dips can persist after the resection of pheochromocytoma and paraganglioma. Patients who develop clinical postoperative hypoglycemia and female sex may serve as indicators for this prolonged susceptibility, suggesting a need for extended monitoring and intervention.</p>\u0000 </section>\u0000 </div>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149321059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urethroplasty for Anterior Urethral Stricture in Men With Non-Muscle-Invasive Bladder Cancer: Feasibility and Durability of a Pragmatic Recurrence-Free Interval-Oriented Strategy. 尿道成形术治疗男性非肌侵性膀胱癌前尿道狭窄:一种实用的无复发间隔定向策略的可行性和持久性。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-01 DOI: 10.1111/iju.70711
Takuya Touge, Akio Horiguchi, Masayuki Shinchi, Madoka Higuchi, Yuhei Segawa, Kazuki Yanagida, Daisuke Kubota, Kenichiro Ojima, Eiji Takahashi, Junichi Asakuma, Daisuke Watanabe, Keiichi Ito
{"title":"Urethroplasty for Anterior Urethral Stricture in Men With Non-Muscle-Invasive Bladder Cancer: Feasibility and Durability of a Pragmatic Recurrence-Free Interval-Oriented Strategy.","authors":"Takuya Touge, Akio Horiguchi, Masayuki Shinchi, Madoka Higuchi, Yuhei Segawa, Kazuki Yanagida, Daisuke Kubota, Kenichiro Ojima, Eiji Takahashi, Junichi Asakuma, Daisuke Watanabe, Keiichi Ito","doi":"10.1111/iju.70711","DOIUrl":"https://doi.org/10.1111/iju.70711","url":null,"abstract":"<p><strong>Objectives: </strong>To report the outcomes of urethroplasty in men with anterior urethral stricture and concomitant non-muscle-invasive bladder cancer, scheduled at least 2 years after the most recent transurethral resection.</p><p><strong>Methods: </strong>We retrospectively reviewed 33 men who underwent urethroplasty for anterior urethral stricture with a history of transurethral resection for non-muscle-invasive bladder cancer. Those wishing to undergo anastomotic or substitution urethroplasty waited until 2 years had elapsed since the most recent resection, with intervention limited to symptom-driven dilation. Others with a stricture confined to the distal anterior urethra were offered ventral meatotomy or perineal urethrostomy without delay. Success was defined as passage of a flexible cystoscope through the reconstructed segment without further intervention.</p><p><strong>Results: </strong>Median stricture length was 15 mm. Anastomotic urethroplasty was performed in 12, dorsal onlay augmentation urethroplasty in 7, perineal urethrostomy in 8, staged urethroplasty in 3, and ventral meatotomy in 3, at a median of 34 months after resection. The seven patients who waited showed no worsening of the stricture. At a median follow-up of 58 months, 28 (84.8%) remained free of re-stricture, stricture-free survival at 5 years was 82.0%, and no re-stricture was symptomatic. Flow rate, residual volume, and patient-reported outcomes improved. Bladder tumor recurred in three, in whom repeat resection was accomplished through the reconstructed urethra without dilation.</p><p><strong>Conclusions: </strong>Urethroplasty scheduled as an institutional approach, not a validated recommendation, at least 2 years after the most recent resection was feasible, provided durable patency, and preserved endoscopic access for bladder cancer management; this interval requires validation in larger cohorts.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149394187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oligoprogression and Metastasis-Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma. 转移性肾细胞癌在全身治疗中的少进展和转移导向治疗。
IF 2.9 3区 医学
International Journal of Urology Pub Date : 2026-11-01 DOI: 10.1111/iju.70716
Takuto Shimizu, Yuki Oda, Nobutaka Nishimura, Yusuke Iemura, Kota Iida, Yoshihiro Tatsumi, Keiichi Sakamoto, Takashi Iwamoto, Kazuki Ichikawa, Masaomi Kuwada, Norimi Takamatsu, Akira Tachibana, Mitsuru Tomizawa, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Dotoh, Yasushi Nakai, Nobumichi Tanaka, Makito Miyake
{"title":"Oligoprogression and Metastasis-Directed Therapy During Systemic Therapy for Metastatic Renal Cell Carcinoma.","authors":"Takuto Shimizu, Yuki Oda, Nobutaka Nishimura, Yusuke Iemura, Kota Iida, Yoshihiro Tatsumi, Keiichi Sakamoto, Takashi Iwamoto, Kazuki Ichikawa, Masaomi Kuwada, Norimi Takamatsu, Akira Tachibana, Mitsuru Tomizawa, Kenta Onishi, Shunta Hori, Yosuke Morizawa, Daisuke Dotoh, Yasushi Nakai, Nobumichi Tanaka, Makito Miyake","doi":"10.1111/iju.70716","DOIUrl":"https://doi.org/10.1111/iju.70716","url":null,"abstract":"<p><strong>Objectives: </strong>To characterize the frequency and clinical patterns of oligoprogression during systemic therapy for metastatic renal cell carcinoma (mRCC) and evaluate outcomes following metastasis-directed therapy (MDT).</p><p><strong>Methods: </strong>We retrospectively reviewed 261 patients with mRCC treated between 2007 and 2025. Oligoprogression was defined as progression in five or fewer lesions despite otherwise controlled disease. Cumulative incidence was estimated using competing-risk analysis. Associations between MDT and treatment-line outcomes were evaluated using time-dependent Cox regression.</p><p><strong>Results: </strong>Among 544 evaluable treatment-line assessments from 261 patients, oligoprogression occurred in 63 (11.6%), representing 63 unique patients. Crude frequencies were 6.1%, 16.7%, and 16.5% during first-, second-, and third-line therapy, respectively. The cumulative incidence was 8.8% at 6 months and 10.8% at 12 months. Fifty-four patients (85.7%) had one or two progressing lesions. MDT was performed in 21 patients, whereas 42 received no MDT. Patients selected for MDT had a lower oligoprogressive lesion burden. In multivariable time-dependent analysis, MDT was not associated with treatment-line escalation alone (hazard ratio [HR], 1.05; 95% confidence interval [CI], 0.41-2.71), but was associated with a lower hazard of treatment-line escalation or death (HR, 0.42; 95% CI, 0.19-0.94). The cumulative incidence of local progression after MDT was 26.7% at 12 months and 39.9% at 24 months.</p><p><strong>Conclusions: </strong>Oligoprogression occurred in a clinically relevant subset of patients with mRCC. Although MDT was associated with favorable composite outcomes, substantial treatment selection limits causal interpretation.</p>","PeriodicalId":14323,"journal":{"name":"International Journal of Urology","volume":"33 11","pages":""},"PeriodicalIF":2.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149406110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书